분석
2026년 8월 31일•1분 읽기
AstraZeneca pays $200M upfront to Sino Biopharma for PDE3/4 inhibitor rights
AstraZeneca has paid $200 million to Sino Biopharmaceutical and secured non‑China rights to PDE3/4 inhibitor TQC3721, aiming to develop a COPD candidate against Merck’s Ohtuvayre.
분석
2026년 8월 23일•1분 읽기
Where to Source Semaglutide: Supplier Guide
A concise guide to the 95 Semaglutide suppliers on Pharmacountry, highlighting key sourcing regions and buyer considerations.
3
1
분석
2026년 8월 23일•1분 읽기
Which Countries Dominate Manufacturing Equipment & Utilities Supply?
China, India, Italy, Germany, and the United States together account for over two‑thirds of active suppliers in Manufacturing Equipment & Utilities on Pharmacountry.
1